ESPR Q4 2018 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$184M

Gross Profit

$135M73.2% margin

Operating Income

-$61M-32.9% margin

Net Income

-$60M-32.5% margin

EPS (Diluted)

$-2.24

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$143M

Total Liabilities

$64M

Stockholders' Equity

$79M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$184M	$0	—
Gross Profit	$135M	-$148M	+191.5%
Operating Income	-$61M	-$39M	-56.7%
Net Income	-$60M	-$38M	-58.5%